Form 4 for ACRV Acrivon Therapeutics, Inc.
Accepted 2026-08-27 16:14:53 ET · period of report 2026-08-25 · accession 0000905148-26-003968 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-27 16:14 | 2026-08-25 | ACRV | Blume-Jensen Peter | Pres, CEO, Dir | S - Sale | $2.21 | -14.0K | 2.23M | -0.6% | -$31.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-25 | S | D | 14,036 | $2.21 | 2,230,052 | D | — | — | (F1) Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units. (F2) The price reported in Column 4 above reflects the weighted average sale price. This transaction was executed in multiple trades at prices ranging from $2.17 to $2.25, inclusive. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in footnote 2 of this Form 4. (F3) These securities are held by President and CEO, Dr. Peter Blume-Jensen, who is also Dr. Kristina Masson's spouse. Dr. Masson disclaims beneficial ownership of such securities except to the extent of her pecuniary interest therein. |